Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors

Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling

(2016) Gary Hattersley et al.   ENDOCRINOLOGY

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

(2016) Paul D. Miller et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture

(2014) Jay S Magaziner et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?

(2014) Felicia Cosman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

(2011) Michael R McClung et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Time since prior fracture is a risk modifier for 10-year osteoporotic fractures

(2010) Lora M Giangregorio et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Timing of Subsequent Fractures after an Initial Fracture

(2010) Tineke A. C. M. van Geel et al.   Current Osteoporosis Reports

Proximal Humeral Fracture as a Risk Factor for Subsequent Hip Fractures

(2009) Jeremiah Clinton et al.   JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME

Hip Fracture Patients at Risk of Second Hip Fracture: A Nationwide Population-Based Cohort Study of 169,145 Cases During 1977–2001

(2009) Jesper Ryg et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density

(2009) Richard Eastell et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM